All In Biotech

Drug Trial Radar · NCT07200375

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Sep 29, 2025

Primary completion

Sep 29, 2029

Study completion Sep 29, 2029

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 1, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • GlofitamabDrug

    Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. real-world Progression-Free Survival (rwPFS)Time frame: Up to approximately 4 years

Locations

22 sites in 2 countries. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, China · Recruiting

  • Peking University Third Hospital

    Beijing, China · Recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, China · Recruiting

  • West China Hospital of Sichuan University

    Chengdu, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, China · Recruiting

  • The First Affiliated Hospital of Ningbo University

    Ningbo, China · Recruiting

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China · Recruiting

  • Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • Tianjin Cancer Hospital

    Tianjin, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China · Recruiting

  • Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

    Wuhan, China · Recruiting

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, China · Recruiting

  • The First Affiliated Hospital of Xian Jiao Tong University

    Xi'an, China · Recruiting

  • Yantai Yu Huangding Hospital

    Yantai, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences.

    Langfang, Hebei, China · Recruiting

  • Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center

    Tianjin, Tianjin Municipality, China · Recruiting

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.